Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
1.080
+0.050 (4.85%)
At close: Mar 9, 2026, 4:00 PM EDT
1.053
-0.027 (-2.51%)
After-hours: Mar 9, 2026, 4:18 PM EDT
Cognition Therapeutics Employees
As of December 31, 2024, Cognition Therapeutics had 28 total employees, including 25 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
28
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$999,500
Market Cap
95.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | 0 | - |
| Dec 31, 2023 | 28 | 3 | 12.00% |
| Dec 31, 2022 | 25 | 4 | 19.05% |
| Dec 31, 2021 | 21 | 1 | 5.00% |
| Dec 31, 2020 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Verrica Pharmaceuticals | 71 |
| PMV Pharmaceuticals | 47 |
| Pyxis Oncology | 44 |
| Vivani Medical | 37 |
| iBio, Inc. | 20 |
| TuHURA Biosciences | 19 |
| MAIA Biotechnology | 13 |
| Dogwood Therapeutics | 12 |
CGTX News
- 7 days ago - Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis - GlobeNewsWire
- 4 weeks ago - Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewsWire
- 5 weeks ago - Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies - GlobeNewsWire
- 2 months ago - Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies - GlobeNewsWire
- 3 months ago - Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 3 months ago - Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 4 months ago - Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease - GlobeNewsWire
- 4 months ago - Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs - GlobeNewsWire